Gen9 is a privately held company with a portfolio of next-generation gene synthesis technologies that enable the high-throughput, automated production of DNA constructs at lower cost and higher accuracy than previous methods. Gen9 was founded in 2009 by Joseph Jacobson (Massachusetts Institute of Technology), George Church (Harvard Medical School) and Drew Endy (Stanford University).
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/25/13 | $21,000,000 | Strategic |
Agilent Technologies | undisclosed |
